Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2,000
Single User License Price INR 135
Corporate User License Price USD 6,000
Corporate User License Price INR 405
Site License Price USD 4,000
Site License Price INR 270
Request a Quote

Report Title

Macular Edema - Pipeline Review, H1 2018

Quote Request for License Type
License Type Price  
Single User License USD 2,000
Site License USD 4,000
Enterprise Wide License USD 6,000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Macular Edema - Pipeline Review, H1 2018


Quote Request for License Type
License Type Price  
Single User License USD 2,000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Macular Edema - Pipeline Review, H1 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Macular Edema - Pipeline Review, H1 2018



Executive Summary

Macular Edema - Pipeline Review, H1 2018

 

Summary

 

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Pipeline Review, H1 2018, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape.

 

Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.

 

Report Highlights

 

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Macular Edema - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

 

The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 7 and 1 respectively.

 

Macular Edema (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Scope

 

- The pipeline guide provides a snapshot of the global therapeutic landscape of Macular Edema (Ophthalmology).

- The pipeline guide reviews pipeline therapeutics for Macular Edema (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Macular Edema (Ophthalmology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Macular Edema (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Macular Edema (Ophthalmology)

 

Reasons to buy

 

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Macular Edema (Ophthalmology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Macular Edema (Ophthalmology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Macular Edema - Overview

Macular Edema - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Macular Edema - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Macular Edema - Companies Involved in Therapeutics Development

ActiveSite Pharmaceuticals Inc

Coherus BioSciences Inc

EyeGate Pharmaceuticals Inc

Lupin Ltd

Mabion SA

OMEICOS Therapeutics GmbH

Promedior Inc

Taiwan Liposome Company Ltd

Xbrane Biopharma AB

Macular Edema - Drug Profiles

ACX-107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASPPDC-020 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexamethasone phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexamethasone sodium phosphate SR 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMT-28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRM-167 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranibizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranibizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranibizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Macular Edema - Dormant Projects

Macular Edema - Discontinued Products

Macular Edema - Product Development Milestones

Featured News & Press Releases

Jul 25, 2017: TLC to Receive Government Grant for Development of Ophthalmology Product Candidate TLC399

Oct 01, 2015: Patent Granted by SIPO for TLCs Ophthalmic Drug Delivery System

Jan 06, 2015: Government Subsidy of NT$17.6M granted for TLC's Ophthalmology Drug Phase I/II trial

Dec 23, 2013: TLC receives FDA IND approval for Sustained Release Macular Disease Drug

Sep 24, 2013: Patent Approval granted by USPTO for TLC's BioSeizer Platform

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Macular Edema, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

List of Tables

Number of Products under Development for Macular Edema, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Macular Edema - Pipeline by ActiveSite Pharmaceuticals Inc, H1 2018

Macular Edema - Pipeline by Coherus BioSciences Inc, H1 2018

Macular Edema - Pipeline by EyeGate Pharmaceuticals Inc, H1 2018

Macular Edema - Pipeline by Lupin Ltd, H1 2018

Macular Edema - Pipeline by Mabion SA, H1 2018

Macular Edema - Pipeline by OMEICOS Therapeutics GmbH, H1 2018

Macular Edema - Pipeline by Promedior Inc, H1 2018

Macular Edema - Pipeline by Taiwan Liposome Company Ltd, H1 2018

Macular Edema - Pipeline by Xbrane Biopharma AB, H1 2018

Macular Edema - Dormant Projects, H1 2018

Macular Edema - Discontinued Products, H1 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

ActiveSite Pharmaceuticals Inc

Coherus BioSciences Inc

EyeGate Pharmaceuticals Inc

Lupin Ltd

Mabion SA

OMEICOS Therapeutics GmbH

Promedior Inc

Taiwan Liposome Company Ltd

Xbrane Biopharma AB

Macular Edema Therapeutic Products under Development, Key Players in Macular Edema Therapeutics, Macular Edema Pipeline Overview, Macular Edema Pipeline, Macular Edema Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand